Intelligence-led Assessment of Pharmaceuticals in the Environment.
The overall aim of this project is to is to develop frameworks that utilize information from toxicological studies, pharmacological mode of action and in silico models to support more intelligent environmental testing of pharmaceuticals in development and to prioritise legacy pharmaceuticals for full environmental risk assessment and/or environmental (bio) monitoring.
iPiE started in January 2015 and is a 48-months IMI-JU funded project with a budget of over 10,2 million €. The work is carried by a consortium of 25 academic institutions, research organizations, pharmaceutical companies and SMEs, led by Bayer.
For more contact information, please visit the following site